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Tumors driven by mutant KRAS are among the most aggressive and refractory to
treatment. Unfortunately, despite the efforts, targeting alterations of this GTPase, either
directly or by acting on the downstream signaling cascades, has been, so far, largely
unsuccessful. However, recently, novel therapeutic opportunities are emerging based on
the effect that this oncogenic lesion exerts in rewiring the cancer cell metabolism. Cancer
cells that become dependent on KRAS-driven metabolic adaptations are sensitive
to the inhibition of these metabolic routes, revealing novel therapeutic windows of
intervention. In general, mutant KRAS fosters tumor growth by shifting cancer cell
metabolism toward anabolic pathways. Depending on the tumor, KRAS-driven metabolic
rewiring occurs by up-regulating rate-limiting enzymes involved in amino acid, fatty
acid, or nucleotide biosynthesis, and by stimulating scavenging pathways such as
macropinocytosis and autophagy, which, in turn, provide building blocks to the anabolic
routes, also maintaining the energy levels and the cell redox potential (1). This review
will discuss the most recent findings on mutant KRAS metabolic reliance in tumor
models of pancreatic and non-small-cell lung cancer, also highlighting the role that these
metabolic adaptations play in resistance to target therapy. The effects of constitutive
KRAS activation in glycolysis elevation, amino acids metabolism reprogramming, fatty
acid turnover, and nucleotide biosynthesis will be discussed also in the context of
different genetic landscapes.
Keywords: KRAS, PDAC, metabolic rewiring, metabolic adaptability in cancer, NSCLC, gluocose metabolism in
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INTRODUCTION
KRAS mutations can promote all the key aspects of cancer cell metabolism. It elevates glucose,
glutamine and fatty acids uptake and consumption to sustain biosynthetic pathways and the cell
redox potential. All these functions are regulated by a number of events, here summarized in three
major points, that cooperate with mutant Kras in metabolic reprogramming and specify metabolic
adaptation in different tumor types.
(i) Similarly to other oncogenic lesions (2), the effect ofKRASmutations inmetabolic adaptation
can differ in distinct tumor types depending on the tissue of origin. This has been revealed by
comparing the metabolic adaptations of non-small cell lung carcinoma (NSCLC) and pancreatic
ductal adenocarcinoma (PDAC) driven by Kras mutations and Trp53 deletion in mice. These
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two cancer types, despite sharing the same genetic alteration,
use branched-chain amino acids differently. While NSCLCs
incorporate free branched-chain amino acids into tissue protein
and use them as nitrogen source, uptake of these amino acids and
expression of key enzymes responsible for their catabolism are
decreased in PDACs (3).
(ii) Cancer cells carrying mutant Kras crosstalk with the
microenvironment, exchanging cytokines, growth factors, and
metabolites to improve metabolic adaptation and overcome low
nutrients availability (4–6).
(iii) Finally, a number of concomitant genetic alterations have
been shown to cooperate with KRAS mutations in sustaining
specific metabolic adaptations (7–10).
In this framework, the purpose of this review is to discuss
the most recent findings on the interplay between Kras and
metabolism focusing on metabolic dependencies of mutant Kras-
driven lung and pancreatic cancers that could be attractive as
therapeutic targets.
MUTANT KRAS AND GLUCOSE
METABOLISM
The involvement of the Ras oncogene in metabolic
reprogramming has been initially revealed by its ability to
promote glycolysis (11). In pancreatic cancer, KRAS mutations
are an early event being detectable in the initial lesions known as
pancreatic intraepithelial neoplasias (PanIN), which can progress
in infiltrating ductal carcinomas through the acquisition of
additional genetic alterations (12). In mouse models, PanIN
lesions rapidly evolve in aggressive PDACs when Krasmutations
are combined with Trp53 loss (13). Elevation of glycolysis is a
distinguishing feature of Kras-driven tumorigenesis. Indeed, in
the Kras mutant NSCLC model, inhibition of increased lactate
production, which results from high rates of glycolysis, severely
impacts on disease progression (14). Moreover, increased
expression of the facilitative glucose transporter GLUT1, which
fosters glycolysis by increasing glucose uptake (15), can be
invariably detected in Kras mutant pancreatic lesions (16, 17)
(Figure 1). The major outcome of increased glycolysis is the
generation of intermediates that can be used as building blocks
by other metabolic routes to synthetize nucleotides, amino
acids, and fatty acids which are required by the rapidly dividing
cells to generate the tumor mass (20). Indeed, elevation of
glycolysis by Kras channels glucose intermediates in the pentose
phosphate pathway (PPP) and in the hexosamine biosynthesis
pathway (21). Using a KrasG12D inducible PDAC murine
model (also carrying deletion of p53), abrogation of KrasG12D
expression causes tumor regression that is accompanied by
severe reduction of the expression of GLUT1 and rate-limiting
glycolytic enzymes, and of the amount of glycolytic intermediates
as revealed by both metabolomics and transcriptomic studies
(21). These metabolites fuel the non-oxidative arm of PPP
whose primary function is to produce the nucleotide precursor
ribose-5-phosphate. Mechanistically, activation of MAPK by
Kras up-regulates Myc-directed transcription. In turn, this
increases the expression of the glycolytic enzymes that promote
glucose uptake and consumption, and of the PPP enzyme
RPIA. RPIA catalyzes the conversion of ribose-5-phosphate
in ribulose-5-phosphate, thus fueling nucleotides biosynthesis
(21, 22). In agreement, inhibition of PPP suppresses xenograft
tumor growth indicating that mutant Kras, by increasing glucose
uptake and consumption, sustains biosynthetic pathways leading
to nucleotide production finally maintaining tumor growth (21).
Interestingly, nucleosides supplementation can rescue cell death
caused by Kras knockdown in mutant Kras-addicted PDAC cell
lines without promoting cell proliferation suggesting that the
metabolic function of Kras can be uncoupled from its functions
in proliferation (22).
The genetic landscape of the tumor cooperates with KRAS
mutations in the elevation of glycolysis to promote cancer
growth and dissemination. In pancreatic cancer, overexpression
of paraoxonase 2 (PON2), a target of p53 transcriptional
repression, has been found to join forces with mutant Kras to
elevate glycolysis. PON2 increases glucose uptake by binding
to GLUT1 thus preventing interaction of the latter with the
inhibitory protein STOM (7). PON2 overexpression controls
the cell starvation response and increases glucose uptake
to protect pancreatic cancer cells from detachment-induced
cell death, which, in part, occurs through suppression of
the AMPK/FOXO3A/PUMA signaling pathway (7). AMPK is
a highly conserved kinase that works as a sensor of low
cellular energy and that can either repress or promote tumor
growth depending on tumor type and context (23). Here,
pharmacological activation of the AMPK pathway inhibits
growth of tumors generated by subcutaneous injection of
PDAC cancer cells revealing a potential metabolic druggable
vulnerability (7).
SCAVENGING PATHWAYS AND AMINO
ACID METABOLISM IN KRAS MUTANT
CANCER CELLS
KRAS mutations are known to stimulate processes such as
macropinocytosis and autophagy that can scavenge nutrients
from, respectively, external and internal compartments to
sustain cancer cell survival under condition of nutrient
deprivation [reviewed in Kimmelman (1)]. Both these two
scavenging pathways generate vesicles, macropinosomes, and
autophagosomes, which ultimately fuse with lysosomes to release
their cargoes for degradation. In the lysosomes, breakdown
of nutrients provides the cell with pools of free amino acids,
lipids, nucleotides and glucose that can be used by the
anabolic pathways for synthetizing novel macromolecules (1, 24).
Interestingly, both in Kras mutant lung and pancreatic cancers,
the lysosomal compartment undergoes expansion thanks to the
increased activity of the transcription factors Tfeb/Tfe3 (25, 26),
which are responsible for lysosomal biogenesis (27, 28). In
Kras-driven NSCLC, glucose starvation activates AMPK that
promotes dephosphorylation and nuclear translocation of Tfeb
and Tfe3 (25). Accordingly, Tfe3 activity is required for growth
of mouse lung tumors and increased expression of lysosomal
genes correlates with accelerated disease recurrence in human
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FIGURE 1 | Representative immunohistochemistry stainings of GLUT1 in sections of pancreas from a wild type mouse (CTR) or from a mouse expressing KrasG12V in
the acinar/centroacinar lineages (Elas-tTA/tetOFF-Cre;K-Ras+/LSL G12V Geo) (18). GLUT1 is up-regulated specifically in most tumor cells, with mixed
membranous/intracellular localization. In each case pancreas was formalin fixed, paraffin embedded and slices were processed as described in Pupo et al. (19).
Briefly, paraffin removal was performed with two 10min steps in Xylene, rehydrated in decreasing concentration of ethanol, and antigen retrieval was performed using
2100 Antigen Retriever/R-Universal buffer (Aptum Biologics). Slices were permeabilized with 0.2% TritonX, saturated in 5% goat serum/BSA and endogenous
peroxidase was inhibited by H2O2 incubation. Staining was performed with anti-GLUT1 antibody (AbCam, 1:200) and secondary antibody anti-Rabbit-HRP (Dako).
Immunoreactivity was developed using DAB chromogen (Dako). Scale bars are 50 µm.
lung adenocarcinoma patients (25). Similarly, upregulation and
increased nuclear residence of Tfe3 sustain pancreatic tumor
growth (26). Of note, overexpression of Mitf, which belongs
to this family of transcription factors, promotes progression of
Kras mutant PanIN lesions in PDAC indicating that increased
lysosomal activity plays a driver function in mutant Kras
tumors (26).
Macropinocytosis is a non-selective actin-dependent
endocytic process that uptakes nutrients from the extracellular
environment in large intracytoplasmatic vesicles (29). In tumors,
macropinocytosis works as a feeding mechanism to overcome
high nutrients demand and support metabolic flexibility and
adaptation. KRAS mutations have been shown to stimulate
macropinocytosis allowing for large uptake of albumin, the
most abundant serum protein, which is degraded in lysosomes
to increase the intracellular pool of amino acids (30, 31).
Breakdown of albumin provides amino acids that feed the central
carbon metabolism (30) and, among them, glutamine, is avidly
used by Kras transformed cells for anaplerosis and nucleotide
production (30, 32) (Figure 2). Indeed, in Kras mutant
pancreatic cancer cells, glutamine is the major carbon source
and is consumed via a non-canonical pathway. In the majority
of non-transformed cells, in mitochondria, glutamine-derived
glutamate is converted, by the enzyme glutamate dehydrogenase
(GLUD1), in α-ketoglutarate to fuel the tricarboxylic acid
(TCA) cycle. Instead, in PDAC cells, glutamate is used by
the mitochondrial aspartate transaminase GOT2 to produce
aspartate and α-ketoglutarate. Aspartate is transported in the
cytoplasm where it is converted to oxaloacetate, by the aspartate
transaminase GOT1, then into malate and pyruvate thus
elevating the NADPH/NADP+ ratio, which, in turn, sustains
the cell redox potential (33) (Figure 2). In agreement, genetic
deletion of any enzyme in the pathway elevates production
of reactive oxygen species, diminishes the amount of reduced
glutathione, and results in suppression of PDAC growth both
in vitro and in vivo (33). Kras drives the alternative glutamine
consumption pathway by up regulating transcription of GOT1
and reducing expression of GLUD1. While this pathway is
essential for PDAC growth, it seems to be dispensable in non-
transformed cells. This offers a therapeutic option to this type of
tumors also considering that its inhibition might synergize with
therapies that increase intracellular reactive oxygen species such
as chemotherapy and radiation (33). Along this line, Kras mutant
cells that have become resistant to cisplatin, a compound that
works by increasing the reactive oxygen species in the cytoplasm,
display elevation of glutamine consumption and anti-oxidant
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FIGURE 2 | The cartoon schematizes some of the effects of mutant Kras in reprogramming amino acid metabolism. The cytoplasm of the cell has been colored in
blue in the background to highlight the role of mutant Kras in PDAC, in pink to represent pathways revealed in NSCLC, in yellow when the mechanisms are common
to both tumor types. Kras potentiates both macropinocytosis and autophagy whose vesicles end up in lysosomes, a compartment that is frequently found enlarged in
Kras mutant cancer cells. In, NSCLC, in condition of low glucose, this occurs by activating AMPK that phosphorylates Tfe3 resulting in its nuclear translocation and
transcription of lysosomal genes. Moreover, AMPK activation increases autophagy initiation and maturation. Breakdown of macromolecules in lysosomes produce free
amino acids available to biosynthetic and energy pathways. Among them glutamine can enter the TCA cycle in mitochondria (depicted on the right). In PDAC
glutamine is consumed through an alternative pathway (highlighted in red and in the box on the right). In NSCLC, mutant Kras activates the PI3K/AKT pathway that, in
condition of low glutamine, favors mRNA expression of the ATF4 transcription factor via the NRF2 factor. In addition, NRF2 is also a key regulator of genes involved in
the antioxidant response. Under condition of asparagine deprivation, the GCN2-eIF2 pathway prompts transduction of the ATF4 mRNA into protein, which, in turn,
activates the transcription of amino acids transporters and glutamine consuming enzymes. Among them, asparagine synthetase ASNS catalyzes the synthesis of
asparagine from glutamine. Asparagine levels and ASNS control proliferation, mTORC1 activation and suppress apoptosis.
capacity (34). Knock down of GOT1 in the resistant cells reduces
their proliferation suggesting that Kras-mediated metabolic
reprogramming of glutamine consumption contributes to the
acquired resistance to platinum-based drugs (34).
The role of Kras in detoxification is also reported in advanced
lung cancer, where high frequency of KrasG12D copy gain is
observed. This enrichment in mutant alleles promote channeling
of glucose-derived metabolites in the TCA cycle and glutathione
biosynthesis enhancing the management of reactive oxygen
species and increasing the metastatic potential (35). It is of note
that upregulation of glutathione is specifically associated with
increased mutant gene copy number highlighting a “dose” effect
and suggesting therapeutic vulnerability (35).
Macroautophagy (here referred as autophagy) promotes
survival under metabolic stress conditions by directing
intracellular components to lysosomes via the formation of
vesicles known as autophagosomes (24). Even if autophagy
does not increment the biomass, as it re-utilizes pre-existing
molecules to generate new ones, it supports cell survival under
stress condition allowing tumor persistence (36). Autophagy
is known to sustain several aspects of Ras transformation,
from maintenance of the cell glycolytic capacity (37), of the
mitochondrial oxidative metabolism (38), of energy charge and
nucleotide pool (39), to the secretion of pro-migratory cytokines
(40). Autophagy has complex functions in cancer, being both
pro-tumorigenic and tumor suppressive (24), but increasing
evidence in mouse models of pancreatic cancer indicates that,
especially at later stages of tumorigenesis, autophagy sustains
tumor growth [reviewed in Amaravadi and Debnath (41)].
Indeed, pancreatic deletion of the autophagy gene Atg5 in a
model of pancreatic cancer driven by oncogenic Kras and the
stochastic loss of heterozygosity of Trp53 (KrasG12D; Trp53lox/+),
a condition that reproduces the stepwise human development
of pancreatic cancer, increases the number of PanIN lesions,
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but impairs the progression of PanIN to PDAC, prolonging
mice survival (42). Moreover, inhibition of autophagy by
treatment with hydroxycloroquine causes tumor reduction
in KRAS mutant TP53 mutant patients-derived pancreatic
cancer xenografts (42). In addition, the effects of intermittent
autophagy inhibition, which would mimic patients treatment,
have been recently tested using an inducible transgenic PDAC
mouse model generated by crossing mice carrying the inducible
dominant-negative mutant of the autophagic gene Atg4B with
the KrasG12D; Trp53lox/+, mice. In these animals, metronomic
impairment of autophagy has been found to delay tumor growth
via both cell autonomous, by decreasing proliferation and
sensitizing apoptosis in nutrient-restricted areas of the tumor,
and non-autonomous, macrophage-mediated, mechanisms (5).
Notably, two recent studies have shown that autophagy
inhibition synergizes with pharmacological targeting of the
KRAS downstream effectors MEK1/2 or ERK, preventing growth
of KRAS-driven pancreatic adenocarcinomas (43, 44). The
efficacy of combining these two treatments appears to rely on
the fact that inhibition of the MAPK pathway, one of the major
pathways downstream KRAS, potentiates autophagy, suggesting
that this treatment causes addiction to autophagy. Concomitant
treatment with MAPK and autophagy inhibitors might therefore
represent a novel strategy to target KRAS-driven cancers (43, 44).
The ability of mutant Kras to model the microenvironment
is a long standing observation in PDACs where abrogation
of KrasG12D expression, not only affects tumor growth, but
also reduces the desmoplastic stroma, which is typical of this
type of cancer (18). In PDACs, mutant Kras instructs the
microenvironment to sustain tumor growth both by engaging
stromal cells that instigate reciprocal signaling (4), and by
exploiting stroma-derived alternative fuels (6). This latter
function relies on the stroma-associated pancreatic stellate cells
that, following stimulation by the cancer cells, activate autophagy
and secrete their breakdown products mainly consisting of non-
essential amino acids. Among them, alanine, the second most
abundant amino acid in proteins, is up-taken by the cancer cells
and used as carbon source to run the TCA cycle, and to synthetize
other non-essential amino acids and lipids (6).
The role of Kras in mediating the nutrient stress response to
reduced amino acid availability has been recently elucidated in
NSCLC. Gene expression profiles of lung cancer cell lines with
different genetic background have been analyzed in presence
of high or low glutamine concentrations with or without
concomitant Kras knockdown, to identify a set of genes that are
differentially regulated by Kras signaling in response to glutamine
availability (45). In low glutamine, Kras regulates over 100 genes.
Among them, 39 are controlled by the transcription factor
ATF4. Kras increases the expression of ATF4 mRNA through
PI3K-AKT-mediated upregulation of the NRF2 transcription
factor, which drives the expression of a number of genes mainly
involved in the antioxidant response [reviewed in Sullivan et al.
(46)]. During nutrient deprivation, activation of the GCN2-
p-eIF2 pathway stimulates translation of the ATF4 mRNA,
resulting in increased ATF4 protein levels and transcription of
target genes responsible for amino acids uptake and metabolism
thus regulating cell proliferation and mTORC1 activation (45).
Among the ATF4 targets, the enzyme asparagine synthetase
(ASNS), which transfers the γ amino group of glutamine
to aspartate, yielding asparagine and glutamate, uncovers a
key role because it contributes to apoptotic suppression,
protein biosynthesis and mTORC1 activation. Consistently,
inhibition of AKT impairs Kras-dependent activation of ASNS
therefore sensitizing NSCLC tumors to depletion of extracellular
asparagine (45). Overall these findings identify KRAS as a master
regulator of the transcriptional response to nutrient deprivation
that controls amino acids uptake and consumption (schematized
in Figure 2). ATF4 has been shown to exert both pro- and anti-
oncogenic effects depending on the genetic context and nutrient
availability (45). In condition of low glutamine, ATF4 has a
protective role toward apoptosis in Kras mutant NSCLC cell
lines that carry loss of KEAP1 (45), a deletion that, in humans,
affects approximately 20% of Kras-mutant lung adenocarcinomas
(8). Keap1 is a ubiquitin ligase that causes degradation of
NRF2 [reviewed in Sullivan et al. (46)]. Its loss cooperates
with KRAS mutations in lung adenocarcinoma progression by
opposing to the oxidative stress barriers during tumorigenesis
(8). Of note, Kras mutant Keap1 deficient cancers are dependent
on the glutamine anaplerotic pathway as their growth rate in
mice is reduced by pharmacological inhibition of the enzyme
glutaminase. This suggests that increased NRF2 activation in
Krasmutant lung cancermight be exploited as a stratification tool
to identify patients that benefit from glutaminase inhibition (8).
In NSCLC, KRAS mutations are often accompanied by
loss of the tumor suppressor STK11, which encodes the
LKB1 kinase, leading to the formation of aggressive tumors
characterized by perturbed nitrogen handling (9). LKB1, through
AMPK, suppresses transcription of CPS1 (carbamoyl phosphate
synthetase-1), a mitochondrial enzyme that catalyzes the rate-
limiting step of the urea cycle. In non-pathological settings,
expression of CPS1 is restricted to the liver where robust
urea production from ammonia takes place (47). In NSCLC
cells bearing both mutant Kras and LKB1 loss, expression of
CPS1 produces carbamoyl phosphate in the mitochondria from
ammonia and bicarbonate, initiating pyrimidine synthesis (9).
Depletion of CPS1 in these cells results in pyrimidine depletion,
replication fork stalling and DNA damage finally reducing
their ability to grow tumors. Interestingly, wild type Kras cells
carrying LKB1 loss express CPS1, but do not depend on it.
Thus oncogenic Kras is required to generate CPS1 “addiction.”
This addiction might result from the ability of mutant Kras
to increase glutaminolysis in mitochondria (33) thus locally
generating ammonia that would support carbamoyl phosphate
production by CPS1 (9).
MUTANT KRAS IN LIPID METABOLISM
Lipid metabolism, in particular the synthesis of fatty acids,
is required for membrane biosynthesis, signaling molecules
production and energy storage (48). Recently, it is also emerging
as a mechanism to cope with oncogenic stress (49). Mutant
Kras has been shown to control both β-oxidation and de novo
lipogenesis in NSCLC (49, 50). The role of mutant Kras in fatty
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TABLE 1 | Summary of potential metabolic targets in PDAC and NSCLC.
Cancer type Potential metabolic targets Proposed mechanism Proposed inhibitor References
PDAC Penthose phosphate pathway
(PPP)
MAPK through Kras leads to an increase of glycolytic
enzymes expression
PPP inhibition (21)
PDAC PON2 Suppresses cell detachment-induced cell death (anoikis)
by inhibiting the AMPK/FOXO3A/PUMA pathway
Pharmacological inhibition of PON2 or
activation of AMPK
(7, 23)
PDAC
NSCLC
Tfeb/Tfe3 Tfe3 sustains tumor growth through increased lysosomal
activity
Inhibition of lysosomal function (25, 26)
PDAC GOT1 and GOT2 Elevating the NADPH/NADP+ ratio leading to higher
antioxidant capacity of tumor cells
GOT1 inhibition (33, 34)
PDAC MAPK (MEK1/2, ERK) and
autophagy pathway
MAPK inhibition leads to tumor cell addiction to
autophagy
Combined inhibition of autophagy and
MAPK in cells addicted to autophagy
(43, 44)
NSCLC ATF4 transcription factor Amino acid dependency Inhibition of glutamine utilization (45)
NSCLC Carbamoyl phosphate
synthetase-1 (CPS1)
KRAS/LKB1 mutant enhances CPS1 expression,
pyrimidine synthesis and glutaminolysis
Inhibition of CPS1 or glutamine utilization (9, 33)
NSCLC Acsl3 Kras enhances Acsl3 activity and lipid metabolism Silencing or inhibition of Acsl3 (49)
PDAC GNAS Promotes cAMP/PKA signaling and metabolism rewiring Inhibitors of the cAMP/PKA pathway and
lipid metabolism
(10)
acid oxidation has been reported in a transgenic mouse model
that expresses the (doxy)-inducible Kras transgene (KrasG12D) in
the respiratory epithelium (49). These mice, when fed with doxy,
develop lung tumors that completely regress when doxycycline is
removed with concomitant significant decrease in the expression
of enzymes that control glycolysis and lipid metabolism (49).
Among the latters, Acyl-coenzyme A synthetase long chain
family member 3 and 4 (Acsl3 and Acsl4) are significantly down
regulated in tumors undergoing KrasG12D extinction and Acsl3
seems to contribute the most to the oncogenic phenotype both
in vitro and in vivo (49). Acsl3 promotes uptake, retention,
and β-oxidation of fatty acids converting them into Acyl-CoA
esters. Genetic deletion of Acsl3 in mice does not cause any
morphological defects neither during development nor adult life,
but impairs mutant Kras tumorigenesis. Acsl3 silencing has likely
similar effects as fatty acid synthase pharmacological inhibition
opening to new possible therapeutic strategies in NSCLS (49).
The role of Kras in lipogenesis is highlighted by the
upregulation of enzymes that control fatty acid metabolism
such as ATP citrate lyase, fatty acid synthase and acetyl
coenzyme A carboxylase in the KrasG12D lung cancer model (50).
Overexpression of both ATP citrate lyase and fatty acid synthase
correlates with poor survival and with increased lipogenesis as
shown by the higher levels of newly synthetized palmitate and
oleate (48, 50).
As for other metabolic adaptations, KRAS mutations
work synergistically with additional genetic alterations in
reprogramming lipid metabolism. In PDAC arising from
intraductal papillary mucinous neoplasm (IPMNs), KRAS
mutations are associated to a gain of function mutation
on the gene GNAS (GNASR201C) which encodes Gαs, the
stimulatory subunit of heterotrimeric G proteins (10). GNAS
mediates G-protein-coupled receptor (GPCR)-stimulated cAMP
signaling, and its mutation has been identified in different
tumor types (10). In double mutant mice carrying inducible
GnasR201C expression and KrasG12D mutation, GnasR201C
promotes IPMN initiation and sustains tumor formation.
Mechanistically, using tumor-derived organoids, GnasR201C has
been found to support pancreatic cancer growth via cAMP-PKA
signaling that suppresses the salt-inducible kinases (SIKs) (10).
Proteomics reveals that this pathway is overall correlated with
lipid metabolism and with components of the peroxisome, an
organelle required for long-chain fatty acids processing and the
generation of ether lipids suggesting that concurrent GNAS and
KRASmutations cooperate in lipid metabolism rewiring (10).
CONCLUSIONS
Studies on the role of mutant Kras in rewiring cancer
cell metabolism are blooming and the approaches to exploit
Kras-driven metabolic vulnerabilities that stem from these
findings hold promises, at least in pre-clinical settings, as
we summarized in Table 1. A take home message is that
metabolic interfering drugs can be attempted, preferentially
in combination with other therapies, to tackle Kras mutant
cancers but, to be successful, these strategies have to consider
the genetic mutational background, the tissue of origin and
the crosstalk between the tumor and the microenvironment.
It is of note that some of the putative targets including
AMPK and autophagy have, depending on the context, pro-
tumorigenic functions, while others, such as ATF4, by regulating
transcription of distinct set of genes, are endowed with a
wide range of downstream functions. This could pose limits to
their exploitation as therapeutic targets (23, 51, 52). Moreover,
findings on the role of AMPK in KrasG12D-driven lung cancer
during glucose starvation (25), and on the KRAS-dependent
transcriptional response to nutrient deprivation (45), reveal that
the effects of KRAS mutations on metabolic reprogramming are
also strongly influenced by the availability of nutrients which
can be heterogeneously distributed within the tumor and change
over time. There is a lot more to be learned, there are still
big research gaps in the field that need to be addressed in
future studies. Moreover the interplay with other pathways,
such as PPARγ and WNT/β-catenin, involved in metabolic
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enzymes changes in other cancers (53, 54) should be further
investigated. This growing body of knowledge points to the
complexity of this system and suggests that analysis of the
genetic context and the metabolic activity of the tumor should
be combined to identify KRAS-driven metabolic vulnerabilities
and stratify patients.
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GLOSSARY
The use of capital letters or the italic to indicate KRAS reflects the
nomenclature guidelines here reported.
KRAS human protein.
KRAS human gene.
Kras murine protein.
Krasmurine gene.
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